Biological dressings and skin substitutes

Overview

Biological and bioengineered skin substitutes exist because autograft is finite. Split-thickness skin graft is still the definitive closure for excised burn wounds, but deep dermal and full-thickness burns grafted with split-thickness autograft alone routinely produce contracture, hypertrophy, pain, and itching ^[1]. In patients with extensive burns the problem compounds: there is not enough donor skin to cover the wound ^[5]. Skin substitutes — biological coverings, dermal scaffolds, and cultured cellular products — are the surgical response to that gap. They reduce evaporative loss, isolate the wound from infection, and either temporize until autograft is available or contribute a regenerated dermal layer that supports a thinner autograft and a better scar.

The product universe is wide and the names blur together at the bedside. Allograft (cadaveric human skin), xenograft (porcine, more recently fish), amniotic and placental membrane, biosynthetic composites such as Biobrane and Suprathel, acellular dermal matrices such as Integra and AlloDerm, and cultured cellular products such as cultured epidermal autograft (CEA) and autologous skin cell suspension (ReCell) all live under this umbrella. They are not interchangeable. Each has an indication, a take-rate profile, a complication signature, and an evidence base of differing quality. The clinical question on rounds is rarely "should we use a skin substitute" — it is "which one, when, and what comes next."

The modern evidence base is stronger than the 1990s skin-substitute era but still uneven. The strongest signals come from systematic reviews and meta-analyses showing that dermal substitutes shorten wound healing time, lower Vancouver Scar Scale scores, and reduce scar hyperplasia compared with traditional treatment ^[6]. In burns over 40% TBSA, allograft cover shortens length of stay versus topical antimicrobial alone ^[19]. In massive burns over 50% TBSA, cell-based wound closure techniques yield the lowest pooled mortality (11%) compared with autograft (50%) and other approaches ^[3]. The opposing signal — that the cultured-cell evidence base remains methodologically thin and standardization is lacking — is honest, recurring, and unresolved ^[7].

Pathophysiology

Skin substitutes act by one of three mechanisms: temporary biological coverage, dermal scaffold ingrowth, or epidermal cell delivery. Temporary biological covers (allograft, xenograft, amniotic membrane) provide a barrier that reduces evaporative loss and bacterial colonization while the wound is prepared for autograft or while a partial-thickness burn re-epithelializes. Allograft is preferred where viable cells in the graft contribute to the wound bed environment; cryopreserved allograft is more viable than glycerol-preserved allograft on histologic confirmation, and the cryopreserved cohort shows lower mortality and shorter length of stay than the glycerol-preserved cohort in severe burn series ^[15].

Dermal scaffolds — Integra dermal regeneration template, MatriDerm, and acellular dermal matrices including AlloDerm — provide a collagen-based template into which the patient's own fibroblasts and vasculature migrate, reconstituting a neodermis. Integra and MatriDerm are both 2 mm-thick bovine collagen templates; the bilayer Integra includes a superficial silicone layer that functions as a temporary epidermis and is removed at the second stage when a thin epidermal autograft is placed ^[12]. Mean take rate of Integra in the postapproval multicenter cohort was 76.2% with a median of 95%, demonstrating that vascularization and integration are reliable when the wound bed is clean and the dressing is managed correctly ^[20]. Complete vascularization of Integra occurs later than for biosynthetic alternatives such as cellulose sponge, which is expected from the longer dermal-template integration window ^[13].

Cultured cellular products deliver cells rather than scaffold. Cultured epidermal autograft (CEA) is grown from a full-thickness skin biopsy expanded over weeks in a manufacturer's facility before being applied as confluent sheets ^[9]. Autologous skin cell suspension (ASCS, ReCell) processes a thin split-thickness biopsy at the point of care into a noncultured spray of keratinocytes, melanocytes, Langerhans cells, and papillary dermal cells capable of epidermal regeneration using minimal donor skin ^[11]. ASCS has been demonstrated to significantly decrease donor skin requirements compared with traditional split-thickness skin graft in burn injuries with an expansion ratio of 1:80 ^[4]. The clinical promise is donor-site economy; the constraint is take rate, which is lower than autograft in massive-burn pooled data ^[3].

Classification

Biological and bioengineered skin substitutes in contemporary burn practice fall into four functional classes. Boundaries are not rigid — Biobrane is a biosynthetic composite with a porcine collagen surface bonded to a nylon mesh, and several cultured products are seeded on a biological or biosynthetic scaffold — but the functional classification helps clinical reasoning at the bedside.

Temporary biological coverings. Allograft (cryopreserved or glycerol-preserved cadaveric skin), porcine xenograft, fish-skin xenograft (acellular Nile tilapia and Atlantic cod), and amniotic and placental membrane. Used as biological wound dressings on partial-thickness burns awaiting re-epithelialization, on excised burn wounds awaiting autograft, and on donor sites. Cryopreserved allograft retains higher viability than glycerol-preserved allograft on histology ^[15]. Tilapia skin xenograft achieved faster reepithelialization, lower pain, and reduced anesthetic requirement compared with silver-impregnated sodium carboxymethylcellulose in a phase II RCT of 62 superficial burn patients ^[10]. Amniotic membrane has been used as a biological wound dressing for over a century and outperforms conventional treatment, silver sulfadiazine, and polyurethane membrane for burn wound healing in pooled data, though it is less effective than honey ^[9].

Acellular dermal matrices (ADM) — bilayer dermal templates and single-stage acellular dermis. Integra dermal regeneration template (bilayer collagen-glycosaminoglycan + silicone, two-stage), MatriDerm (single-layer collagen-elastin, can be used in one stage), AlloDerm (acellular human dermis), and xenogeneic ADM products. Used to reconstitute a dermal layer in deep dermal and full-thickness burns, in scar contracture release, and over exposed bone or tendon. Multicenter postapproval data on Integra in 216 burn patients with mean TBSA 36.5% reported a mean take rate of 76.2%, median 95% ^[20]. One-step composite grafting of acellular dermis with autologous ultra-thin split-thickness skin in 1,208 patients across three centers produced a higher one-week wound healing rate and better six-month Vancouver Scar Scale scores than single-layer autograft, at higher cost ^[5]. Pooled meta-analysis of 1,596 burn patients across 16 studies of xenogeneic ADM dressings showed shorter wound healing time and lower VSS scores compared with controls, though publication bias was present and the bias risk of the included studies was rated uncertain ^[6].

Biosynthetic composites. Biobrane (silicone-nylon-collagen composite) and Suprathel (absorbable polylactide membrane). Used predominantly on superficial-to-mid partial-thickness burns and on donor sites. In pediatric partial-thickness burns, Biobrane heals significantly faster than beta-glucan collagen (median 9 versus 13 days, hazard ratio 1.68), with shorter inpatient length of stay ^[14]. Biobrane outperformed silver sulfadiazine on pain, length of stay, and healing time in pediatric partial-thickness scald burns ^[21]. Suprathel produced no significant healing-time difference compared with Omiderm in second-degree burns but significantly lower pain scores ^[17]. The biosynthetic class fills the partial-thickness niche where atraumatic dressing changes and patient comfort matter most.

Cultured cellular products. Cultured epidermal autograft (CEA, marketed as Epicel), autologous skin cell suspension (ASCS, ReCell), and emerging engineered cellular composites. Used in massive burns where donor skin is the limiting resource. In a 5-year multicenter retrospective review of 40 patients with mean TBSA 56% treated with CEA on posterior burns, the engraftment rate was 83% with overall survival of 90% ^[8]. ASCS combined with widely meshed autograft achieved noninferior 8-week closure (65% versus 58%) versus standard meshed autograft, while requiring 27.4% less donor skin ^[4]. ReCell compared with split-thickness skin grafting in deep partial-thickness burns produced a donor area approximately 40 times smaller than control with significantly faster donor-site healing, similar pain and scar outcomes, and 98% versus 100% wound healing at 4 weeks ^[11].

Assessment

Selection of a biological dressing or skin substitute starts with the same three questions that drive any burn wound decision: depth, size, and trajectory. Wound depth is the primary indication for a dermal substitute, with a one-stage approach recommended for deep dermal to full-thickness wounds larger than 10 cm² and a two-stage approach for the same depth wounds with limited donor sites or exposed bone or tendon ^[1]. Superficial partial-thickness burns can be managed with a temporary biological cover (Biobrane, amniotic membrane, fish-skin xenograft) or with a topical antimicrobial; the decision turns on dressing-change burden, pain, and resource availability. Deep partial-thickness and full-thickness burns are headed for excision and need either autograft, allograft as a temporary cover, or a dermal regeneration template if scar quality and reconstruction matter.

Donor-site reserve drives the second decision. In small burns, autograft is sufficient and skin substitutes are an adjunct. In massive burns the donor-site economy question dominates: how much wound can be closed with how much donor skin? Cultured products and ASCS exist to extend donor reserve. Patients with greater than 30% TBSA burns are considered for CEA at high-volume centers because superficial partial-thickness burns can convert to deep partial or full thickness over the first hospital days, and early biopsy submission to the manufacturer is required to have CEA available when needed ^[8]. The lead time for CEA — typically 2 to 4 weeks — is a planning variable that has no analogue in topical antimicrobial selection.

Trajectory matters because biological covers and dermal templates require a viable wound bed. Contraindications to dermal substitute use include established wound infection and allergy to matrix components ^[1]. The wound must be excised to viable tissue, hemostasis must be adequate, and the dressing must be applied with attention to fixation, drainage, and monitoring. If the wound is contaminated or eschar incompletely debrided, the substitute will fail to take and any benefit over topical alone is lost. Negative-pressure wound therapy has emerged as an adjunct to bolster skin grafts and promote integration of bilaminate dermal substitutes such as Integra.

Management

Partial-thickness burns

Biosynthetic and biological covers compete with silver-based topicals for partial-thickness burn management. The signal across head-to-head trials is consistent: faster healing, lower pain, and fewer dressing changes with covers. In pediatric superficial scald burns covering 5 to 25% TBSA, Biobrane reduced healing time and pain medication requirement compared with topical antimicrobials without increasing infection risk ^[22]. In pediatric second-degree burns, Biobrane was superior to 1% silver sulfadiazine on pain, hospital length of stay, and wound healing time with no infections in either group ^[21]. In a separate pediatric trial, Biobrane heals significantly faster than beta-glucan collagen with shorter inpatient stay ^[14]. Amniotic membrane outperforms conventional treatment, silver sulfadiazine, and polyurethane membrane in pooled data for burn wound healing ^[9].

The biosynthetic-versus-silver pattern has limits. Biobrane was equivalent to Duoderm on healing time and pain in a pediatric intermediate-thickness burn RCT, with Duoderm cheaper and a reasonable first-line option ^[26]. In adult scald burns at one center, retrospective review found Biobrane was associated with a perceived increase in infection, secondary deepening, surgery, and length of stay, suggesting that scald burns in adults may not show the pediatric superficial-burn benefit ^[25]. The clinical anchor is that depth, age, and burn pattern determine whether a biosynthetic cover earns its premium over a topical regimen.

Suprathel offers a different tradeoff in the partial-thickness niche: equivalent healing time to Omiderm in second-degree burns but significantly lower pain scores ^[17]. The clinical role is patient-comfort-driven. Where dressing-change pain is the bottleneck, Suprathel and Biobrane both reduce that burden compared with daily-topical regimens.

Deep dermal and full-thickness burns

Deep dermal and full-thickness burns headed for autograft benefit from a dermal layer. Integra dermal regeneration template is the prototype two-stage system: surgical excision to viable tissue, application of the bilayer template, integration over 2 to 3 weeks while a fibrovascular neodermis forms, removal of the silicone layer, and placement of a thin epidermal autograft ^[20]. The postapproval multicenter cohort of 216 patients with mean TBSA 36.5% achieved a mean take rate of 76.2% (median 95%) with invasive infection rate 3.1% and superficial infection 13.2% ^[20]. The clinical use case is full-thickness burns where scar quality matters, exposed bone or tendon prevents direct autograft, or limited donor reserve makes a thinner autograft over a regenerated dermis preferable to a thicker autograft alone.

MatriDerm is the single-layer alternative — a 2 mm bovine collagen-elastin template that can be used in one stage with simultaneous autograft placement ^[12]. In a long-term comparative study of 12 patients per template treated for burn scar contracture release, both Integra and MatriDerm produced improvement in mobility and skin quality, with the Integra bilayer showing the best performance in retraction rate, skin quality, and mobility recovery ^[12]. The one-stage versus two-stage decision turns on wound bed quality, donor availability for the second-stage epidermal autograft, and surgeon experience.

Acellular dermal matrices used in one stage with ultra-thin split-thickness skin produce a higher one-week wound healing rate and better six-month VSS scar scores than single-layer autograft alone, at higher hospitalization cost ^[5]. The xenogeneic ADM meta-analysis pooling 1,596 patients showed shorter wound healing time and lower VSS scores compared with controls, with reduced scar hyperplasia, complications, and skin grafting in the ADM group ^[6]. The ADM signal across product categories points the same direction: a regenerated dermal layer improves scar quality, with the cost penalty offset in part by the reduced need for revision.

Massive burns and donor-site economy

Massive burns — TBSA 50% or greater — are the indication where biological covers and cultured cellular products move from optional to essential. Early wound coverage is one of the most essential factors influencing survival of extensively burned patients, especially those with TBSA greater than 50% ^[3]. In patients with limited donor sites available for autografting, techniques such as the Meek micrograft procedure or cultured epidermal allograft have proven viable alternatives ^[3]. In the systematic review and meta-analysis of 30 studies and 1,369 patients with massive burns ≥50% TBSA, advantages in mortality, length of stay, graft take, and number of required surgeries were seen for the Meek and CEA groups ^[3]. Mortality was highest in patients treated with autografts (50%) and lowest with cell-based therapy (11%), and graft take was highest with autografts (96%) and lowest with cell-based therapy (72%) ^[3]. The cell-based mortality advantage is large; the take-rate disadvantage is the operational price.

Allograft cover earns its place in this population. In 16 patients with greater than 40% TBSA second-degree burns treated with early debridement and homograft cover compared with 13 patients treated with twice-daily silver sulfadiazine, hospital length of stay was reduced (P < 0.01) ^[19]. In a clinical trial of 118 patients with TBSA 30 to 75%, biological dressing (Xenoderm) produced mortality of 10.8% versus 35% with conventional treatment (P = 0.001), with mean hospital stay 18.2 versus 31.3 days and mean dressing changes 9.9 versus 22.1 ^[16]. Cryopreserved allograft outperformed glycerol-preserved allograft on mortality (25% versus 34.8%) and length of stay (39.2 versus 45.9 days), differences that did not reach statistical significance but trended consistently with the higher viability of cryopreserved tissue on histology ^[15].

CEA in protocolized use at a high-volume burn network produced 83% engraftment and 90% overall survival in 40 patients with mean TBSA 56% on posterior burns ^[8]. Patients with greater than 30% TBSA burns at participating centers are identified early for CEA so that the full-thickness skin biopsy can be sent to the manufacturer for processing in time ^[8]. ASCS combined with widely meshed autograft achieved noninferior 8-week closure (65% versus 58% control) while using 27.4% less donor skin in a 65-patient multicenter RCT — the donor-site economy gain that defines the clinical case for ASCS in massive burns ^[4].

Hand and reconstructive applications

The hand is a special case because functional outcome and contracture prevention drive product selection. In pediatric hand burns, full-thickness skin grafts produced a statistically significant decrease in post-graft contracture (OR 0.35, P = 0.0001) and in later surgical releases (OR 0.06, P = 0.00001) compared with split-thickness skin grafts, with better functional ability — though split-thickness grafts were superior on scar appearance and color and less hair growth was observed ^[18]. In burned hands treated with Integra, functional results support the indication where dermal substitution improves long-term gliding and scar pliability.

Dermal substitutes are also a workhorse in burn reconstruction. The 2025 systematic review on dermal substitutes for acute burns and reconstructive surgery confirms that wound depth is the primary indication, that one-stage approaches fit deep dermal to full-thickness wounds larger than 10 cm², and that two-stage approaches fit the same depth with limited donor reserves or exposed bone or tendon ^[1]. The same review found no definitive age or burn-location thresholds, though careful consideration is advised for electrical and chemical burns, and limited data exist for use in patients with diabetes, chronic vascular disease, or immunocompromise ^[1].

Application, fixation, and monitoring

Each product class has its own application discipline. Biobrane is applied to a clean partial-thickness wound or excised wound bed, secured with surgical glue or staples, and inspected for adherence at 24 to 48 hours. Detached areas are trimmed; well-adhered areas are left until re-epithelialization. Integra is applied to a freshly excised wound bed, secured to wound edges, and dressed with a non-adherent contact layer plus bolster. The silicone layer is monitored for fluid collections, hematoma, or infection; aspiration of seromas is straightforward, but established infection requires removal. Negative-pressure wound therapy bolsters the template in the integration window.

Allograft and xenograft are applied as biological dressings to excised wounds or partial-thickness burns. Allograft is replaced when it begins to incorporate and reject (typically 2 to 4 weeks) or in staged sequence as the wound is autografted in segments. Amniotic membrane and placental allografts are applied with the chorionic side oriented per product instructions, and replacement intervals follow the product's biological half-life on the wound. CEA sheets are placed on a clean wound bed with meticulous fixation and overlying dressing; engraftment is monitored at 5 to 7 days. ASCS is sprayed on the wound bed plus widely meshed autograft and dressed with a non-adherent layer, with re-epithelialization assessed at 1 to 2 weeks.

Complications

Three complication categories matter most: take failure, infection, and donor-site morbidity (for cultured products). Take failure is the largest operational concern with dermal templates. Mean take rate of Integra in the postapproval cohort was 76.2% with median 95%, meaning a meaningful minority of grafts fail to integrate ^[20]. Causes include hematoma, seroma, mechanical disruption, and infection. The remedy is meticulous wound bed preparation, hemostasis, and immobilization plus negative-pressure adjunct where the anatomic site permits.

Infection is the next concern. Integra-treated sites in the postapproval cohort showed 3.1% invasive infection (95% CI 2.0-4.5%) and 13.2% superficial infection (95% CI 11.0-15.7%) ^[20]. Infection rates with biological dressings vary by product and clinical context; Biobrane in pediatric superficial scald burns under 25% TBSA showed no signal of increased infection risk ^[22], while a single-center retrospective review of adult scald burns found a perceived increase in infection with Biobrane compared with topical hydrogel ^[25]. The clinical anchor is that biological substitutes require a clean wound bed; established infection is a contraindication to placement ^[1].

Donor-site morbidity is a direct rationale for cultured cellular products. ReCell donor area is approximately 40 times smaller than control split-thickness donor area, with significantly faster donor-site healing in the ReCell group ^[11]. ASCS combined with widely meshed autograft uses 27.4% less donor skin than standard meshed autograft ^[4]. The clinical case for these products is precisely that they reduce or replace the secondary wound that autograft creates.

Allograft and xenograft carry small risks of disease transmission and immune response. Cryopreserved allograft is more viable than glycerol-preserved allograft on histology, and viable allograft cells contribute to wound bed environment but are also recognized as foreign and eventually rejected ^[15]. Amniotic membrane in pooled meta-analysis of 11 RCTs and 816 participants showed no reports of disease transmission or adverse reactions ^[9]. Tilapia skin xenograft and porcine xenograft have similar safety profiles when processed under contemporary tissue-banking standards.

Special Considerations

Pediatric burn care

Biosynthetic and biological covers have a strong evidence base in pediatric partial-thickness burns. In 89 children with superficial scald burns covering 5 to 25% TBSA, Biobrane reduced healing time without increasing infection risk compared with conservative treatment ^[22]. In 20 pediatric second-degree burn patients randomized to Biobrane versus 1% silver sulfadiazine, the Biobrane group had less pain, less pain medication, and shorter length of stay and wound healing time ^[21]. In 235 pediatric partial-thickness burns, Biobrane outperformed beta-glucan collagen on healing time (median 9 vs 13 days, hazard ratio 1.68) and trended toward shorter inpatient length of stay ^[14].

Pediatric reconstructive choices favor full-thickness skin grafting where contracture prevention matters most. In the meta-analysis of 532 pediatric hand burn grafts across 10 non-randomized trials, full-thickness skin grafts reduced post-graft contracture (OR 0.35, P = 0.0001) and later surgical releases (OR 0.06, P = 0.00001) compared with split-thickness grafts, with better functional ability — though split-thickness grafts produced better scar appearance, color match, and less hair growth ^[18]. Selection turns on the specific clinical priority.

Reconstructive applications

Burn reconstruction depends heavily on dermal substitutes for contracture release, exposure of vital structures, and aesthetic outcome. Dermal substitutes are currently employed alongside split-thickness skin grafting to enhance clinical outcomes, though their indications remain a subject of ongoing debate ^[1]. The 2025 systematic review identified wound depth as the primary indication, recommended one-stage approaches for deep dermal to full-thickness wounds larger than 10 cm², and recommended two-stage approaches for the same depth wounds with limited donor reserves or exposed bone or tendon ^[1]. No definitive age or burn-location thresholds were identified in the same review, with careful consideration advised for electrical and chemical burns ^[1].

Cost and access

Cultured products and dermal templates are expensive. One-step composite acellular dermis with ultra-thin split-thickness skin grafting in 1,208 patients across three centers had higher total hospitalization and operation costs than single-layer autograft, though it produced better one-week wound healing rate and six-month VSS scores ^[5]. The cost-effectiveness case turns on reduced revision surgery, shorter length of stay, and improved functional outcome rather than on dressing-change burden alone. Access is uneven: CEA requires a 2 to 4 week lead time and a manufacturer relationship; ReCell requires the harvesting device and operator training; Integra and MatriDerm require surgeon familiarity with two-stage and one-stage technique respectively. Resource-limited settings often default to allograft, amniotic membrane, or biosynthetic covers because the supply chain is shorter.

Outcomes

The most robustly demonstrated outcomes across biological dressings and skin substitutes are shorter wound healing time and lower scar scores compared with controls. Xenogeneic ADM dressings in 1,596 burn patients produced significantly shorter wound healing time and lower VSS scores (standardized mean differences of −2.50 and −3.10 respectively), with reduced ratios of scar hyperplasia, complications, skin grafting, and bacteria detection ^[6]. Amniotic membrane was more effective than conventional treatment, silver sulfadiazine, and polyurethane membrane for burn wound healing ^[9]. Tilapia skin xenograft achieved faster reepithelialization, lower pain, and reduced anesthetic requirement compared with silver-impregnated carboxymethylcellulose ^[10].

Mortality data are most striking in massive burns. In the meta-analysis of 30 studies and 1,369 patients with TBSA ≥50%, cell-based therapy produced the lowest mortality (11%) compared with autografts (50%) and other approaches, with the tradeoff that cell-based therapy had the longest length of stay (91 days) and lowest graft take (72%), while Meek micrografting had the shortest length of stay (50 days) ^[3]. Allograft cover with early excision in burns over 40% TBSA shortens hospital length of stay versus topical antimicrobial alone ^[19]. Biological dressing in 30 to 75% TBSA burns produced mortality of 10.8% versus 35% with conventional treatment, mean hospital stay of 18.2 versus 31.3 days, and 9.9 versus 22.1 dressing changes ^[16].

Scar quality outcomes are also load-bearing. In the comparative study of Integra versus MatriDerm for burn scar contracture release, both produced improvement in mobility and skin quality, with the bilayer Integra showing the best performance in retraction rate, skin quality, and mobility recovery ^[12]. One-step ADM with ultra-thin split-thickness skin produced better six-month VSS scar scores than single-layer autograft alone ^[5]. Take rate is the operational outcome that constrains the others: dermal substitutes integrate at ~76% mean (Integra postapproval), CEA engrafts at ~83% in protocolized use, and ASCS achieves noninferior closure to standard autograft at substantially lower donor-site cost ^[20][8][4].

Controversies and Evidence Gaps

Cultured cell products: promise versus standardization

The cultured cellular evidence base is the largest single controversy in this space. The 2024 systematic review of 14 articles found that various tissue-engineered skin substitutes — from cultured epidermal autografts to dermal regeneration templates seeded with cultured cells — show promising outcomes, with several substitutes exhibiting take rates comparable to STSG with improved scar quality, but standardization of cultured skin substitutes and robust clinical trials with larger populations and appropriate comparators are still lacking ^[7]. The mortality advantage of cell-based therapy in massive burns is striking but the take-rate disadvantage is real, and the lack of standardized protocols across centers makes meta-analytic synthesis fragile ^[3][7]. The pilot RCT of epidermal blister grafting found that cellular treatment yielded healing with less erythema closer to surrounding normal skin (p = 0.0404), with results favoring cellular over acellular technique for partial-thickness burns — but the study itself called for larger areas and larger sample size in further studies ^[24]. The cultured-cell field needs the head-to-head, adequately powered, multicenter trials that have not yet been done.

Head-to-head among dermal templates

Comparative data on Integra versus MatriDerm versus AlloDerm versus xenogeneic ADM products are limited. The Integra-MatriDerm comparison in 12 patients per template for burn scar contracture release showed both produced improvement, with the bilayer Integra showing better retraction rate, skin quality, and mobility recovery ^[12]. The Integra-versus-cellulose-sponge-versus-autograft RCT in 10 adult patients found equal clinical appearance and histological findings at 12 months despite different vascularization timelines, suggesting that the dermal-template choice may matter less for long-term outcome than for the integration window ^[13]. The xenogeneic ADM meta-analysis pooled across 16 studies but had uncertain bias risk in all included studies and demonstrated publication bias for wound healing time, VSS score, and complication ratio ^[6]. The clinical takeaway is that the dermal-template class is collectively effective, but ranking within the class is not yet supported by adequately powered head-to-head data.

Biobrane in adult scald burns

The pediatric Biobrane evidence base is favorable ^[21][22][14], but the adult scald-burn signal is mixed. A single-center retrospective review found Biobrane in adult scalds was associated with increased infection, secondary deepening, surgery, and length of stay compared with topical hydrogel ^[25]. The Biobrane-versus-Duoderm pediatric RCT showed equivalent healing and pain at lower cost for Duoderm ^[26]. The conservative position is that Biobrane earns its place where pediatric superficial-burn cohort selection matches the trial populations and where dressing-change burden and pain are the bottleneck; in adult scald burns, the local center's experience and infection-control posture should drive selection.

Amniotic membrane and standardization

Amniotic membrane has been used for over a century and outperforms conventional treatment, silver sulfadiazine, and polyurethane membrane in pooled meta-analytic data, but the 2021 meta-analysis of 11 RCTs and 816 participants concluded that the evidence needs to be strengthened by further robust randomized controlled trials ^[9]. Variability in amniotic membrane processing (fresh, glycerol-preserved, gamma-irradiated, dehydrated, decellularized, viable cryopreserved placental allograft) produces heterogeneous products with different biological activities, complicating cross-study synthesis. The clinical use case is well established for partial-thickness burns and select reconstructive applications; the standardization gap means that center-level outcomes data drive product selection more than product-class meta-analysis.

Silk and other emerging materials

Silk dressings show promise by reducing the need for frequent changes, allowing wound evaluation due to transparency, exerting antibacterial properties, and minimizing scarring, though silk is not yet widely adopted in clinical settings, and larger high-quality studies are needed to confirm these findings ^[2]. Fish-based biomaterials have received substantial research attention with phase II RCT data supporting tilapia skin xenograft ^[10], though most fish-based products are still classified as supplements outside the surgical-product market ^[23]. The frontier moves quickly; the evidence base for any individual product trails the marketing claims by years.

References

[1] van den Bosch AS, Verwilligen RAF, Pijpe A, et al. "Indications for the use of dermal substitutes in patients with acute burns and in reconstructive surgery after burns: A systematic review." Wound Repair Regen 2025. PMID: 39727218

[2] Vermoesen L, De Decker I, Verbelen J, et al. "The use of silk dressings in the treatment of skin injuries: A systematic review." Burns 2025. PMID: 40010055

[3] Haug V, Tapking C, Panayi AC, et al. "Outcome comparison of the most commonly employed wound coverage techniques in patients with massive burns ≥50% TBSA - A systematic review and meta-analysis." Burns 2024. PMID: 39322501

[4] Henry S, Mapula S, Grevious M, et al. "Maximizing wound coverage in full-thickness skin defects: A randomized-controlled trial of autologous skin cell suspension and widely meshed autograft versus standard meshed autograft." J Trauma Acute Care Surg 2024. PMID: 38098145

[5] Chen L, Yang J, Wang DY, et al. "Multicenter effect analysis of one-step acellular dermis combined with autologous ultra-thin split thickness skin composite transplantation in treating burn and trauma wounds." Int Wound J 2024. PMID: 37548136

[6] You AJ, Li WJ, Zhou JL, Li C. "[Meta-analysis of the effects of xenogeneic acellular dermal matrix dressings in the treatment of wounds in burn patients]." Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi 2023. PMID: 36878527

[7] Simaey M, De Decker I, Vanlauwe F, et al. "The added value of cultured cells in burn treatment: A systematic review." Burns 2024. PMID: 39447287

[8] Homsombath B, Mullins RF, Brandigi C, et al. "Application and Management of Cultured Epidermal Autografts on Posterior Burns - A 5-Year, Multicenter, Retrospective Review of Outcomes." J Burn Care Res 2023. PMID: 35604809

[9] Yang C, Xiong AB, He XC, et al. "Efficacy and feasibility of amniotic membrane for the treatment of burn wounds: A meta-analysis." J Trauma Acute Care Surg 2021. PMID: 33284236

[10] Lima Júnior EM, De Moraes Filho MO, Costa BA, et al. "Innovative Burn Treatment Using Tilapia Skin as a Xenograft: A Phase II Randomized Controlled Trial." J Burn Care Res 2020. PMID: 31900475

[11] Holmes IV JH, Molnar JA, Carter JE, et al. "A Comparative Study of the ReCell Device and Autologous Split-Thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries." J Burn Care Res 2018. PMID: 29800234

[12] Vana LPM, Battlehner CN, Ferreira MA, et al. "Comparative long-term study between two dermal regeneration templates for the reconstruction of burn scar contractures in humans: Clinical and histological results." Burns 2020. PMID: 31645293

[13] Lagus H, Sarlomo-Rikala M, Böhling T, Vuola J. "Prospective study on burns treated with Integra, a cellulose sponge and split thickness skin graft: comparative clinical and histological study - randomized controlled trial." Burns 2013. PMID: 23880091

[14] Lesher AP, Curry RH, Evans J, et al. "Effectiveness of Biobrane for treatment of partial-thickness burns in children." J Pediatr Surg 2011. PMID: 21929986

[15] Kua EH, Goh CQ, Ting Y, Chua A, Song C. "Comparing the use of glycerol preserved and cryopreserved allogenic skin for the treatment of severe burns: differences in clinical outcomes." Cell Tissue Bank 2012. PMID: 21484230

[16] Hosseini SN, Mousavinasab SN, Rahmanpour H, Fallahnezhad M. "A biological dressing versus 'conventional' treatment in patients with massive burns: a clinical trial." Ulus Travma Acil Cerrahi Derg 2009. PMID: 19353315

[17] Schwarze H, Küntscher M, Uhlig C, et al. "Suprathel, a new skin substitute, in the management of partial-thickness burn wounds: results of a clinical study." Ann Plast Surg 2008. PMID: 18216512

[18] Alsaif A, Karam M, Hayre A, et al. "Full thickness skin graft versus split thickness skin graft in paediatric patients with hand burns: Systematic review and meta-analysis." Burns 2023. PMID: 36280545

[19] Naoum JJ, Roehl KR, Wolf SE, Herndon DN. "The use of homograft compared to topical antimicrobial therapy in the treatment of second-degree burns of more than 40% total body surface area." Burns 2004. PMID: 15302419

[20] Heimbach DM, Warden GD, Luterman A, et al. "Multicenter postapproval clinical trial of Integra dermal regeneration template for burn treatment." J Burn Care Rehabil 2003. PMID: 12543990

[21] Barret JP, Dziewulski P, Ramzy PI, et al. "Biobrane versus 1% silver sulfadiazine in second-degree pediatric burns." Plast Reconstr Surg 2000. PMID: 10626971

[22] Lal S, Barrow RE, Wolf SE, et al. "Biobrane improves wound healing in burned children without increased risk of infection." Shock 2000. PMID: 11028549

[23] Gomathy M, Paul AJ, Krishnakumar V. "A Systematic Review of Fish-Based Biomaterial on Wound Healing and Anti-Inflammatory Processes." Adv Wound Care (New Rochelle) 2024. PMID: 37166397

[24] Blome-Eberwein S, Schwartz A, Pinataro C, et al. "Epidermal-cell-based therapy as an adjunct to healing second degree burns-A randomized controlled pilot study." Burns 2023. PMID: 36195486

[25] Krezdorn N, Könneker S, Paprottka FJ, et al. "Biobrane versus topical agents in the treatment of adult scald burns." Burns 2017. PMID: 27507189

[26] Cassidy C, St Peter SD, Lacey S, et al. "Biobrane versus duoderm for the treatment of intermediate thickness burns in children: a prospective, randomized trial." Burns 2005. PMID: 16023298